AUPH AURINIA PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AURINIA PHARMACEUTICALS INC reported revenue of $83.2M (up 18.9% from a year earlier), net income of $37.4M and diluted EPS of $0.28; over the last four quarters revenue was $312M and net income $314M; for the fiscal year ended December 2025 revenue was $283M, up 20.4% on the year before.

AUPH annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $283M, gross profit n/a, operating income $105M, net income $287M (margin 101.5%), EPS $2.07
• Fiscal year ended Dec 2024: revenue $235M, gross profit n/a, operating income −$4.69M, net income $5.80M (margin 2.5%), EPS $0.04
• Fiscal year ended Dec 2023: revenue $176M, gross profit n/a, operating income −$91.7M, net income −$78.0M (margin -44.4%), EPS −$0.54
• Fiscal year ended Dec 2022: revenue $134M, gross profit n/a, operating income −$111M, net income −$108M (margin -80.7%), EPS −$0.76
• Fiscal year ended Dec 2021: revenue $45.6M, gross profit n/a, operating income −$181M, net income −$181M (margin -396.9%), EPS −$1.40

AUPH quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $83.2M (up 18.9% year over year), net income $37.4M, EPS $0.28
• Quarter ended Mar 31, 2026: revenue $77.7M (up 24.4% year over year), net income $34.4M, EPS $0.25
• Quarter ended Dec 31, 2025: revenue $77.1M (up 28.8% year over year), net income $211M, EPS $1.53
• Quarter ended Sep 30, 2025: revenue $73.5M (up 8.4% year over year), net income $31.6M, EPS $0.23
• Quarter ended Jun 30, 2025: revenue $70.0M (up 22.4% year over year), net income $21.5M, EPS $0.16
• Quarter ended Mar 31, 2025: revenue $62.5M (up 24.2% year over year), net income $23.3M, EPS $0.16
• Quarter ended Dec 31, 2024: revenue $59.9M (up 32.8% year over year), net income $1.43M, EPS $0.01
• Quarter ended Sep 30, 2024: revenue $67.8M (up 24.3% year over year), net income $14.4M, EPS $0.10
• Quarter ended Jun 30, 2024: revenue $57.2M (up 37.8% year over year), net income $722K, EPS $0.01
• Quarter ended Mar 31, 2024: revenue $50.3M (up 46.2% year over year), net income −$10.7M, EPS −$0.07
• Quarter ended Dec 31, 2023: revenue $45.1M (up 58.6% year over year), net income −$26.9M, EPS −$0.19
• Quarter ended Sep 30, 2023: revenue $54.5M (down 2.3% year over year), net income −$13.4M, EPS −$0.09
• Quarter ended Jun 30, 2023: revenue $41.5M (up 47.2% year over year), net income −$11.5M, EPS −$0.08
• Quarter ended Mar 31, 2023: revenue $34.4M (up 59.1% year over year), net income −$26.2M, EPS −$0.18
• Quarter ended Dec 31, 2022: revenue $28.4M (up 21.5% year over year), net income −$26.0M, EPS −$0.18
• Quarter ended Sep 30, 2022: revenue $55.8M (up 280.3% year over year), net income −$8.99M, EPS −$0.06
• Quarter ended Jun 30, 2022: revenue $28.2M (up 325.8% year over year), net income −$35.5M, EPS −$0.25
• Quarter ended Mar 31, 2022: revenue $21.6M (up 2266.0% year over year), net income −$37.6M, EPS −$0.27
• Quarter ended Dec 31, 2021: revenue $23.4M, net income −$33.3M, EPS −$0.25
• Quarter ended Sep 30, 2021: revenue $14.7M, net income −$50.3M, EPS −$0.39

AUPH cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $136M, share buybacks $98.2M
• Fiscal year ended Dec 2024: operating cash flow $44.4M, share buybacks $40.2M
• Fiscal year ended Dec 2023: operating cash flow −$33.5M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$79.5M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$158M, share buybacks n/a

AUPH balance sheet

• Jun 30, 2026: cash $180M, total assets $792M, total liabilities $177M, shareholders' equity $615M
• Mar 31, 2026: cash $40.7M, total assets $724M, total liabilities $156M, shareholders' equity $568M
• Dec 31, 2025: cash $80.2M, total assets $752M, total liabilities $170M, shareholders' equity $581M
• Sep 30, 2025: cash $72.9M, total assets $528M, total liabilities $162M, shareholders' equity $366M
• Jun 30, 2025: cash $52.9M, total assets $503M, total liabilities $167M, shareholders' equity $335M
• Mar 31, 2025: cash $66.1M, total assets $505M, total liabilities $155M, shareholders' equity $350M
• Dec 31, 2024: cash $83.4M, total assets $551M, total liabilities $173M, shareholders' equity $377M
• Sep 30, 2024: cash $36.6M, total assets $549M, total liabilities $161M, shareholders' equity $388M

What is AUPH's revenue?

AURINIA PHARMACEUTICALS INC reported $312M of revenue over its last four quarters, through June 30, 2026.

Is AUPH profitable?

Yes. AURINIA PHARMACEUTICALS INC earned $314M over the last four quarters.

What is AUPH's EPS?

Diluted earnings per share over the last four quarters were $2.29; $0.28 in the latest quarter.

AUPH ownership and insider trades · All stocks